Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Invested Capital: 2021-2025

Historic Invested Capital for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $247.7 million.

  • ARS Pharmaceuticals' Invested Capital rose 23.22% to $247.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.7 million, marking a year-over-year increase of 23.22%. This contributed to the annual value of $256.8 million for FY2024, which is 11.28% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Invested Capital is $247.7 million, which was up 28.77% from $192.3 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Invested Capital ranged from a high of $369.0 million in Q1 2021 and a low of -$31.3 million during Q4 2021.
  • For the 3-year period, ARS Pharmaceuticals' Invested Capital averaged around $231.2 million, with its median value being $230.8 million (2023).
  • Over the last 5 years, ARS Pharmaceuticals' Invested Capital had its largest YoY gain of 972.70% in 2022, and its largest YoY loss of 20.54% in 2022.
  • Over the past 5 years, ARS Pharmaceuticals' Invested Capital (Quarterly) stood at -$31.3 million in 2021, then spiked by 972.70% to $272.9 million in 2022, then declined by 15.44% to $230.8 million in 2023, then climbed by 11.28% to $256.8 million in 2024, then rose by 23.22% to $247.7 million in 2025.
  • Its last three reported values are $247.7 million in Q3 2025, $192.3 million for Q2 2025, and $229.0 million during Q1 2025.